Brokers Set Expectations for ADCT FY2025 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ADC Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.66) per share for the year. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

A number of other equities research analysts have also issued reports on ADCT. Stephens started coverage on ADC Therapeutics in a research note on Friday, November 8th. They issued an “overweight” rating and a $6.00 target price for the company. Guggenheim reiterated a “buy” rating and set a $10.00 price objective on shares of ADC Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research note on Monday, January 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $8.00.

ADC Therapeutics Stock Performance

NYSE ADCT opened at $1.72 on Wednesday. The firm has a market capitalization of $165.82 million, a price-to-earnings ratio of -0.72 and a beta of 1.55. ADC Therapeutics has a one year low of $1.68 and a one year high of $6.04. The company’s 50 day moving average price is $2.11 and its 200 day moving average price is $2.75.

ADC Therapeutics (NYSE:ADCT) last issued its earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). The company had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $18.76 million. During the same quarter in the prior year, the firm earned ($0.58) EPS.

Insider Buying and Selling at ADC Therapeutics

In other ADC Therapeutics news, major shareholder Redmile Group, Llc purchased 100,000 shares of ADC Therapeutics stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $3.04 per share, for a total transaction of $304,000.00. Following the transaction, the insider now owns 13,145,712 shares of the company’s stock, valued at $39,962,964.48. The trade was a 0.77 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ADCT. Redmile Group LLC grew its holdings in shares of ADC Therapeutics by 2.6% in the 3rd quarter. Redmile Group LLC now owns 15,669,217 shares of the company’s stock worth $49,358,000 after acquiring an additional 400,000 shares during the last quarter. State Street Corp boosted its position in shares of ADC Therapeutics by 11.6% in the 3rd quarter. State Street Corp now owns 1,106,011 shares of the company’s stock valued at $3,484,000 after purchasing an additional 114,715 shares during the period. Geode Capital Management LLC increased its stake in ADC Therapeutics by 15.6% in the 3rd quarter. Geode Capital Management LLC now owns 953,171 shares of the company’s stock worth $3,002,000 after purchasing an additional 128,454 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in ADC Therapeutics during the 2nd quarter worth about $1,500,000. Finally, Bank of New York Mellon Corp purchased a new stake in ADC Therapeutics during the second quarter valued at about $648,000. Institutional investors own 41.10% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.